DNA Methylation and Primary Immune Thrombocytopenia  by Li, Huiyuan et al.
DNA Methylation and Primary Immune
Thrombocytopenia
Huiyuan Li, Min Xuan and Renchi YangDNA methylation is a heritable, stable, and also reversible way of DNA modification; it can0037-1963
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S116regulate gene expression without changing the nucleotide sequences. Because it takes part in
regulation of immune responses, the loss of methylation homeostasis in immune cells will
result in autoimmune disease by inducing aberrant gene expression. Primary immune
thrombocytopenia (ITP) is an acquired autoimmune disease with many immune deficiencies.
Recently, it was well documented that abnormal DNA methylation is also involved in the
etiology of ITP. In this review, we elucidate the role of DNA methylation in autoimmune
diseases by summarizing the DNA methylation-sensitive genes and the relationship between
DNA methylation and ITP.
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he autoimmune diseases are a series of
disorders with various and complex defects
in the immune system; the etiologies for
some of them remain unclear today. Although DNA
sequence changes have been claimed to be associ-
ated with susceptibility to disease onset, the different
concordance rate of autoimmune diseases between
monozygotic twins indicates that environment also
participates in the development of autoimmunity.1–4
These environmental factors effect immunity mainly
by altering epigenetic regulation, which ultimately
results in changes in gene expression.5,6 DNA meth-
ylation is an epigenetic process that refers to herit-
able chromatin-based mechanisms in the regulation
of gene expression without DNA alternation. This
modification of DNA is time- and cell-specific, and
thus it plays an important role in the regulation of
many pathology processes, such as embryonic devel-
opment, X chromosome inactivation, genomic
imprinting, and cellular differentiation.7–10blished by Elsevier Inc.
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DNA methylation is mediated by DNA methyl-
transferases (DNMTs) through the addition of a
methyl group from S-adenosylmethionine (SAM) to
the fifth carbon of cytosine residues in CG dinucleo-
tides.11 There are five members in DNMT group:
DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L.
The function of DNMT1 is to methylate the hemi-
methylated sites generated during DNA replication.
As the maintenance DNMT, it is implicated in
stabilizing DNA methylation patterns during cell
division.12 DNMT3A and 3B are known as de novo
DNA methyltransferases; they are responsible for the
establishment of DNA methylation patterns during
fetal development. In addition, DNMT3A and
DNMT3B also exhibit non-overlapping functions in
this procedure, with DNMT3B being specifically
required for methylation of centromeric minor satel-
lite repeats.13,14 DNMT2 is not essential for global de
novo or maintenance methylation of DNA because of
its weak DNA methyltransferase activity; instead, it
acts on methylation of small RNA.15–17 DNMT3L is
crucial for the establishment of maternal genomic
imprints but lacks key methyltransferase motifs; it is
more likely to act as a regulator of methylation by
recruiting histone deacetylase (HADC) and stimulat-
ing de novo methylation by DNMT3A.18–20
DNA methylation is a stable but reversible epige-
netic modification; thus DNA demethylation, which
contributes to changes in the DNA methylation
pattern, is also vital for biological processes. DNA
demethylation includes passive and active mecha-
nisms. Passive mechanisms require DNA replicationgy, Vol 50, No 1, Suppl 1, January 2013, pp S116–S126
Figure 1. DNA methylation can repress gene transcrip-
tions. DNA methylation is mediated by DNA methyl-
transferases (DNMTs) through the addition of a methyl
group from S-adenosylmethionine (SAM) to the fifth
carbon of cytosine residues in CG dinucleotide. On the
one hand, these methyl groups can inhibit gene expres-
sion directly by blocking transcription complex binding
to DNA. On the other hand, methylated DNA may be
bound by proteins known as methyl-CpG-binding
domain proteins (MBDs). MBDs can further recruit his-
tone deacetylases (HADC), that eventually alter chroma-
tin structures and lead to inaccessible transcription. Red
hexagon stands for methyl group. Pol II: RNA polymerase
II; TF: transcription factors.
DNA methylation and primary ITP S117by inhibition of DNMTs.21 The active process is
independent of DNA replication; it occurs by remov-
ing the methyl group by demethyltransferases, such
as methyl-CpG-binding domain (MBD) proteins.22
DNA methylation can repress transcription
through several mechanisms (Figure 1). First, methyl
groups inhibit gene expression directly by blocking
transcription complex binding to DNA.23 Second,
MBDs (MBD1, MBD2, MBD3, MBD4, and MECP2) are
attracted to the methylated CpG dinucleotide. Since
the binding of these proteins on methylated DNA
also prevented the binding of transcription complex,
MBDs were reported to be transcriptional repressors
as well as DNA demethylases. In addition, MBDs can
recruit HADC, eventually altering chromatin struc-
tures and leading to inaccessible transcription.24,25
The DNA methylated status of a genome is influ-
enced by several factors. First, the 5-methylcytosine
content in DNA declines with age, suggesting that
the methylated level is related to the proliferative
potential of organs.26 Meanwhile, the DNA methy-
lated level is different between males and females. As
women have two X chromosomes, a high level of
DNA methylation is used to inactivate one X chro-
mosome. This X-inactivation results in women having
equivalent X chromosome gene products as males.9
In addition, food, drug, and environmental factors
also impact DNA methylation.5,6,27,28DNA METHYLATION AND AUTOIMMUNITY
Normal T cells treated with the DNA methylation
inhibitor 5-azacytidine induce autologous B-cell differ-
entiation and T-cell proliferation, and ultimatelyinitiate autoimmunity.29,30 Thus, DNA methyltransfer-
ase inhibitors, such as procainamide and 5-azacytidine,
are sufficient to induce a lupus-like disease.31
In addition, the lymphocytes of systemic lupus eryth-
ematosus (SLE) and rheumatoid arthritis (RA) manifest
global DNA hypomethylated status due to the abnor-
mal expressions of DNMTs and MBDs,32 which further
demonstrates that DNA methylation plays a key role in
autoimmune diseases.
What is the reason for hypomethylation in some
autoimmune diseases? There is evidence that the
impaired ERK and ras-MAPK pathway signaling in
T cells results in decreased expression of DNMT1
and DNA hypomethylation.33,34 This defective
methylation capacity finally generates autoimmun-
ity mainly through inducing overexpression of
methylation-sensitive genes that are engaged in
autoreactive immune responses in lymphocyte,
including IL-4, IL-6, CD70, and FoxP3 among others
(Table 1).CD11a
Lymphocyte function-associated antigen 1 (LFA-
1, CD11a/CD18) is a leukocyte cell surface hetero-
dimer. It promotes intercellular adhesion by bind-
ing to members of the intercellular adhesion
molecule family in immunological and inflamma-
tory reactions.35 The expression of LFA-1 is tissue-
specific through the regulation of methylation and
chromatin structure.36 Normal T cells treated with
DNA methylation inhibitors had increased CD11a
expression directly for demethylation of the CD11a
promoter.37,38 Lu et al. found that the specific
sequence flanking the CD11a promoter was hypo-
methylation in T cells from patients with active
lupus or in normal T cells treated with 5-
azacytidine and procainamide. Patch methylation
of this region can suppress CD11a promoter func-
tion, which illustrated that altered methylation of
specific genes may be relevant to the pathogenesis
of lupus.39CD70
CD70 is a costimulatory molecule of the tumor
necrosis factor super family. It is expressed on
activated dendritic cells, B cells, and T cells. CD27,
the CD70 receptor, is also expressed on activated
immunocytes. CD70–CD27 signaling provides a cos-
timulatory signal for T-cell activation and survival.
CD70 is another methylation-sensitive gene that is
overexpressed in normal T cells treated with DNA
methylation inhibitors, and these overexpressed
CD70 contribute to overstimulated B cells and
increased IgG production.40,41 In SLE patients,
CD70 expression is significantly elevated and
Table 1. Summary of DNA Methylation Involved in Autoimmune Diseases
Disease
Global DNA
Methylation Levels
Methylation-
Associated
Enzymes
Methylation-Sensitive Genes
Genes
Methylation
Status Expression
SLE Hypomethylation79,80 DNMT1k79 CD70,42 CD40,73 IL-4
and IL-6,52 IL-13,83
DNMT3A,
3Bk81
IL-2,69 perforin,60
CD11a,39 CD5,77
Hypomethylation Increase
MBD2, MeCP
m82
protein phosphatase
2,85, IL-10 and IL-1
recepor 2,32
5-hydroxytryptamine
receptor 1A,84
others86–89
RA Hypomethylation90 DNMT1m CD40L,71 IL-6,63
CXCL12,91 IL-1
recepor 232
Hypomethylation Increase
MBD2 m90 IL-1032,92 Inconsistent Decrease
Death receptor-393 Hypermethylation Decrease
Psoriasis Inconsistent94,95 DNMT1m p15 and p21,96
protein tyrosine
phosphatase-198
Hypomethylation Increase
NBD2,
MeCPk95
p1495 Hypermethylation Decrease
p1697,99 Inconsistent
MS Hypomethylation100 Protein tyrosine
phosphatase-1101
Hypermethylation Decrease
Peptidyl
argininedeiminase
2100,102
Hypomethylation Increase
SS Hypomethylation72,79,103 DNMT1k CD70,44,99 CD40L72 Hypomethylation Increase
MBD3, MBD4
k79
T1D Hypermethylated104 DNMT3Bm56 Insulin,104 FoxP356 Hypermethylation Decrease
UC Hypermethylated DNMT1,
DNMT3Bm105
Multidrug resistance
1,106 p16,107
p14,108 estrogen
receptor-1, tumor
suppressor
candidate-3,109
others105
Hypermethylation Decrease
Protease-activated
receptor 2110
Hypomethylation Increase
Abbreviations: SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; MS, multiple sclerosis; SS, systemic sclerosis; T1D, type 1
diabetes; UC, ulcerative colitis; DNMT, DNA methyltransferase; MBD, methyl-CpG-binding domain protein.
H. Li, M. Xuan and R. YangS118correlates with a decrease in CD70 promoter meth-
ylation in CD4þ T cells compared to healthy controls,
as the consequence of the decreased expression of
DNMT1.42 Besides SLE, the reduction of methylation
in CD70 promoter also causes overexpression of
CD70 in many other autoimmune diseases, such as
primary Sjo¨gren’s syndrome, systemic sclerosis (SS),
and immune thrombocytopenia (ITP).43–45Inerleukin-4 and Interferon-g
Interferon (IFN)-g is the typical cytokine of Th1cells, which is mainly engaged in macrophage acti-
vation. Interleukin (IL)-4 is the typical cytokine of
Th2 cells, which generally respond by inducing
antibody production. The balance between Th1
and Th2 subsets has been implicated in the regu-
lation of many immune responses.46 CD4þ T cells
DNA methylation and primary ITP S119treated with 5-azacytidine or procainamide secrete
relatively large amounts of IL-4 and IFN-g,31,47 imply-
ing that DNA methylation participates in T-cell
differentiation. Further studies show that the IFN-g
and IL-4 genes are methylated in human naive
CD4þ T cells. After stimulation via T-cell receptor
(TCR), the IFN-g promoter becomes hypermethy-
lated in Th2 cells, whereas it is hypomethylated in
Th1 cells. Hypermethylation in Th2 cells results in
chromatin condensation and exclusion of cAMP
response element binding protein (CREB) from
IFN-g promoter.48,49 Accordingly, the promoter of
IL-4 locus becomes specifically demethylated in Th2
cells, but becomes methylated during Th1 differ-
entiation.50 The hypomethylation of the IL-4 pro-
moter in the pathogenesis of SLE and asthma might
be important through upregulating the level of
IL-4.51,52FoxP3
The expression of forkhead box P3 (FoxP3) is
regulated by epigenetics. It is unmethylated in
natural regulatory T cells (nTreg), but heavily methy-
lated in naive CD4þ T cells, activated CD4þ T cells,
and peripheral transforming growth factor (TGF)-b–
induced Tregs. Thus, FoxP3 DNA demethylation
constitutes the most reliable criterion for natural
Tregs available at present.53,54 During T-cell activa-
tion in vitro, a DNA demethylation agent, 5-Aza-
2’-deoxycytydine, can induce Foxp3 expression in
CD4þCD25-Foxp3- cells via altering methylation
status of a conserved element in the 5’-untranslated
region of the Foxp3 gene. In addition, the methyl-
ation status within the Foxp3 locus in CD4þ T cells
is associated with the expression of DNMT1 and
DNMT3B, and knocking down the DNMT1
induces FoxP3 expression.55,56 In latent autoim-
mune diabetes (LADA) in adultsthe FoxP3 promoter
region is hypermethylated in CD4þ T cells from
LADA patients compared with the healthy cohort,
which may contribute to disease onset and progres-
sion of LADA.56Perforin
Perforin is a cytotoxic effector molecule
expressed in natural killer cells and a subset of T
cells, and it contributes to target cell killing.57 As a
methylation-sensitive gene, the perforin promoter
region is hypomethylated in primary CD8þ cells,
which express perforin, but is largely methylated in
primary CD4þ T cells, which do not.58,59 It has been
reported that perforin is overexpressed in CD4þ T
cells from active, but not inactive SLE patients, and
this overexpression is related to hypomethylation of
the perforin promoter in primary CD4þ T cells.60,61IL-6
IL-6 activates various cell types carrying the
membrane bound IL-6 receptor; its signaling plays
a pivotal role in controlling the differentiation and
activation of T and B lymphocytes. Treatment with
5-aza-2’ deoxycytidine induces a high level of IL-6 in
MCF-7 (a breast carcinoma cell line) via its gene
hypomethylation, which demonstrated that IL-6
expression is influenced by DNA methylation.62 In
SLE patients, the hypomethylation of the CpG islands
of the IL-6 promoter occurred in T cells and corre-
lates with symptom severity.52 In addition, the
hypomethylated status of a single CpG in the IL-6
promoter region, such as CpG motif at -74 bp or -
1099 bp may augment serum levels of IL-6, implicat-
ing a potential role in the pathogenesis of RA and
chronic periodontitis.63,64 In turn, IL-6 may exert
many epigenetic changes in cells via increasing
expression and activity of DNMTs.65IL-2
IL-2, a key cytokine affecting proliferation and
activation of T and B lymphocytes, is also regulated
by DNA methylation. During T-cell, B-cell, and macro-
phage activation, a small region in the promoter-
enhancer of IL-2 was demethylated; this demethylated
CpG site recruits Oct-1, and induces changes in
histone modifications, finally eliciting IL-2 gene
expression.66,67 Furthermore, the expression of sev-
eral potential enzymes/co-enzymes in relation to the
DNA demethylation pathways such as DNMT1,
DNMT3A, and MBD4 seemed to be associated with
immune cell activation by regulating the expression
of IL-2.68 Downregulated IL-2 expression is a hallmark
of SLE T lymphocytes and is linked to overproduction
of the transcription regulatory factor cAMP-
responsive element modulator (CREM)a, which binds
to a CRE site within the IL-2 promoter and results in
epigenetic changes in T lymphocytes through
DNMT3A-directed DNA hypermethylation and his-
tone deacetylase-1–directed deacetylation.69CD40 Ligand
CD40 ligand (CD40L), a costimulator expressed
on CD4þ T cells, is a response to B-cell activation
and immunoglobulin (Ig) class-switch; it is a
methylation-sensitive gene that is encoded by X
chromosome. Normal CD4þ T cells treated with
demethylation agent overexpress CD40L mRNA
and induce autologous B-cell activation and plasma
cell differentiation. All of these effects can be
reversed by anti-CD40L antibody.70 In patients with
SLE, RA, primary biliary cirrhosis, or SS, demethyla-
tion of CD40L regulatory elements on the inactive
H. Li, M. Xuan and R. YangS120X chromosome contributes to CD40L overexpres-
sion in CD4þ T cells, which may in part explain the
female preponderance of autoimmunity.71–74CD5
CD5þ B cells, also called B1 cells, play important
roles in the production of high-affinity auto-antibodies;
thus they participate in autoimmunity. CD5 has two
isoforms: E1A and E1B. E1A is the full-length and
transmembrane-directed protein, whereas E1B is a
truncated isotype that remains in the cytoplasm.75
Accordingly, EIA can translocate the Src homology 2
(SH2)-containing tyrosine phosphatase-1 (SHP-1) to
the vicinity of the B-cell receptor and raise its thresh-
old, thereby limiting the response of autoreactive B
cells. In contrast, the truncated variant E1B stays in the
cytoplasm, where it can bind to SHP-1 and prevent its
effects.76 The expression of E1B is regulated by DNA
methylation. In SLE patients, the promoter for the
alternative E1B isoform is demethylated in B cells from
patients but not in healthy controls. This finally results
in elevated intracellular E1B levels.77,78Others
In addition to the above-mentioned, a large num-
ber of methylation-sensitive genes still refer to the
pathogenesis of autoimmune diseases (Table 1).
Nonetheless, because of the prevalence of CpG
islands in genomes, the methylation-sensitive genes
related to autoimmune diseases must be more com-
plex than we can imagine. Further research is clearly
needed to better understand methylation-sensitive
genes in autoimmunity.DNA METHYLATION AND ITP
Primary ITP is an acquired autoimmune disease
characterized by decreased platelet count due to
both increased platelet destruction and insufficient
platelet production.111 More than one mechanism
could contribute to ITP, including autoreactive B
lymphocytes, Th1/Tc1 polarization, T-cell–mediated
platelet lysis, abnormal circulating Treg cells, and so
on.112–116 However, until now, the etiology of ITP
was incompletely understood. Like in some auto-
immune diseases described above, DNA methylation
also participates in the pathophysiology of ITP.Global DNA Methylation Levels in ITP Patients
S-adenosylmethionine (SAM) and S-adenosyl-
homocysteine (SAH) are the donor and receptor of
methyl group in the cellular methyltransferase reac-
tion; thus SAM/SAH can be used as an indicator of
cellular methylation status. The SAM/SAH ratio inplasma directly correlates with that in lymphocytes,
and can reflect cellular methylation levels.117,118
We measured serum concentrations of SAM and
SAH in ITP patients and normal controls using
high-performance liquid chromatography, and found
that the plasma SAH level was significantly elevated
in ITP patients compared with normal controls.81
In addition, although the SAM/SAH ratio has a
tendency to decrease in ITP patients, no significant
differences were observed between ITP patients and
controls.81,119 Because SAH has a higher affinity for
the methyltransferase active site than SAM,120 ele-
vated SAH can bind to and inhibit the effect of
DNMTs; thus we speculated that lymphocyte DNA
hypomethylation may exist in ITP through elevated
plasma SAH levels. However, upregulated SAH also
can be explained by an increase in DNA methylation,
suggesting DNA hypermethylation. Thus further
study on the DNA methylation status in ITP patients
has been done. Chen et al further assessed global
methylation by quantifying the methylcytosine con-
centration of genomic DNA.121 The result revealed
that CD4þ T cells had a low DNA methylcytosine
content in ITP patients, which prompted the con-
clusion that the hypomethylation pattern occurred
in CD4þ T cells of ITP patients. However, the
methylation levels seem irrelevant to clinical param-
eters, including age, sex, clinical course, and platelet
counts.121 Based on these findings, we speculate that
the aberrant DNA methylation may take part in the
pathogenesis of ITP.Abnormal Expression of DNA Methylated
Enzymes in ITP Patients
The aberrant DNA methylation status is mostly
induced by abnormal expression of methylation
associated enzymes/co-enzymes. Tao et al found that
the mRNA expressions of DNMT3A and DNMT3B
were downregulated in peripheral blood mononu-
clear cells (PBMCs) of ITP patients compared with
normal controls. This might be due to the elevated
plasma SAH concentrations.81 Consistent with this
result, EL-Shiekh et al found DNMT3A mRNA expres-
sion in PBMCs was significantly decreased, while the
plasma SAH level was elevated in patients with ITP
compared with healthy controls. Thus they specu-
lated that aberrant DNA methylation status, reflected
by decreased mRNA expression of DNMT3A and
increased plasma SAH level, may engage in the
pathogenesis of ITP.119 However, Ma et al came to
a contrary conclusion through the measurement of
mRNA expressions of DNMTs in CD4þ T cells from
ITP patients.45 They found that DNMT1, DNMT3A,
and DNMT3B were all elevated in CD4þ T cells from
ITP patients, and speculated that DNMTs also work
as demethyltransferases as well as methyltransferases
DNA methylation and primary ITP S121in ITP patients.45 In addition, the detection of mRNA
expressions of MBDs showed that the mRNA expres-
sion of MBD2 and MBD4 were decreased both in
PBMCs and CD4þ T cells in ITP patients compared
with those of normal controls,121 which is different
from the result observed in SLE patients.79 The
possible explanation for this discrepancy could be
the Th1/Th2 polarization in ITP and the fact that
IFN-g expression was restricted by MBD2.122
Methylation-Sensitive Genes in ITP Patients
As a methylation-sensitive gene, aberrant methyl-
ation of CD70 is also involved in the etiology of ITP.
Firstly, Ma et al detected the expression of CD70 on
CD4þCD8þ T cells and CD19þ B cells and found that
both the mRNA and protein expressions of CD70
were both increased in CD4þ T cells from ITP
patients, but there was no statistical difference in
CD8þ or CD19þ cells between ITP patients and
healthy controls.123 They further detected the DNA
methylation indices by polymerase chain reaction
(PCR) amplification and high-resolution melting anal-
ysis, the result of which demonstrated that the
methylation levels of the promoter region of CD70
in ITP were lower than those found in healthy
controls. In addition, they found a negative correla-
tion between methylation indices and CD70 mRNA
levels in ITP patients and healthy controls. Thus the
elevated expression of CD70 may be caused by the
hypomethylated promoter region of CD70.45 This
upregulated CD70 can facilitate the survival of T and
B lymphocytes, apoptosis of platelets, and secretion
of IFN-g, finally accelerating the progress of ITP.123
It is clear that abnormal T-cell immunity including
Th1, Th2, Treg, and cytotoxic T lymphocyte (CTL)
promotes the development of ITP. As a methylation-
sensitive gene, FoxP3 is the key transcription factor
for differentiation of Tregs. Moreover, IFN-g, IL-4 and
perforin are major cytokines secreted by the Th1, Th2,
and CTL, respectively. To determine the role of DNA
methylation in ITP, Zhao et al124 investigated the
relationship between the mRNA expressions of the
IFN-g, IL-4, FoxP3, and perforin genes and the meth-
ylation status of their respective promoters in PBMCs
from ITP patients. However, although the methylation
rate of CpGs located at -409 of perforin and the whole
methylation of the IFN-g gene were higher than those
of normal controls, they did not find any negative
correlation between the mRNA expression of these
genes and the methylation status of their promoters.Single-Nucleotide Polymorphism and DNA
Methylation Defect in ITP Patients
Single-nucleotide polymorphism (SNP) is the most
common form of human genetic variation, and maybe influence the expression or activity of the protein
that was encoded by the mutated gene. This will
ultimately result in abnormal biological processes.
Several genes in the DNA methylation pathway have
been subject to genetic association studies in ITP
patients.
Chen et al detected the149C4T SNP (rs2424913)
in the promoter of DNMT3B, but did not find any
significantly difference in either genotypes or allelic
distribution between ITP patients and normal con-
trols.125 This result was confirmed by Shaheen et al.126
In addition, Zhao et al found that there was also no
significant difference of another DNMT3B SNP
579G4T (rs1569686) in genotype and allele distri-
bution between the ITP patients and normal con-
trols.127 Thus it is shown that neither of the two
SNPs of DNMT3B can be used as markers to predict
the susceptibility to ITP.
MBD4 is different from the other members of the
MBD family. It preferentially binds to 5mCpG –TpG
mismatches and removes the mismatched thymine or
uracil, and thus it is thought to act as a DNA repair
enzyme that minimizes mutations at methyl-CpG.128
Zhao et al129 investigated the association between
MBD4 rs140693 polymorphism and the risk for ITP in
a Chinese population. However, there was no signifi-
cant difference in genotype and allele distribution
between the ITP patients and the controls. Similar
results were observed between the two groups when
stratified by age and disease course, including acute
childhood, chronic childhood, acute adult, and
chronic adult. In conclusion, MBD4 polymorphism
may not be a marker to predict the susceptibility to
ITP, at least in the Chinese population.129CONCLUSION
In this review, we have shed light on the impor-
tant role DNA methylation plays in autoimmune
diseases, including ITP, by regulating the expression
of methylation-sensitive genes. Thus the identifica-
tion of a methylation-sensitive gene in ITP will
provide a clinical marker of diagnosis, disease pro-
gression, and therapy. In addition, for the reversi-
bility of DNA methylation, the site-specific
methylated modification may be effective for the
treatment of active ITP patients. However, the
research about DNA methylation in ITP is still in its
preliminary stage, and further experiments are
needed to explore its role in ITP.Acknowledgments
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